scispace - formally typeset
M

Markus Hanner

Researcher at Merck & Co.

Publications -  18
Citations -  1988

Markus Hanner is an academic researcher from Merck & Co.. The author has contributed to research in topics: Binding site & Calcium-activated potassium channel. The author has an hindex of 16, co-authored 18 publications receiving 1908 citations.

Papers
More filters
Journal ArticleDOI

Purification, molecular cloning, and expression of the mammalian sigma1-binding site

TL;DR: The deduced amino acid sequence was structurally unrelated to known mammalian proteins but it shared homology with fungal proteins involved in sterol synthesis, in agreement with the known ability of sigma1-binding sites to interact with steroids, such as progesterone.
Book ChapterDOI

Pharmacology of Potassium Channels

TL;DR: Potassium channels represent the largest and most diverse family of ion channels and are postulated to be involved in a variety of physiologic processes, such as control of cell excitability, release of neurotransmitters, secretion of hormones, regulation of fluid secretion, and clonal expansion of cells of the immune system.
Journal ArticleDOI

Oxidative regulation of large conductance calcium-activated potassium channels.

TL;DR: The results obtained suggest that oxidation enhances specific voltage-dependent opening transitions and slows the rate-limiting closing transition in the Slo channel, and may represent an important link between cellular electrical excitability and metabolism.
Journal ArticleDOI

Complex Subunit Assembly of Neuronal Voltage-gated K+Channels BASIS FOR HIGH-AFFINITY TOXIN INTERACTIONS AND PHARMACOLOGY

TL;DR: In vivo subunit coassembly provides the structural basis for toxin binding pharmacology and can lead to the association of as many as three distinct channel subunits to form functional K+channels in vivo.
Journal ArticleDOI

High affinity of sigma1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase

TL;DR: Investigating if sterol C8–C7 isomerase inhibitors are high affinity ligands for the (+)‐[3H]‐pentazocine labelled sigma1‐binding site demonstrates that sigma 1‐binding protein and yeast isomerases are not only structurally but also pharmacologically related.